It was indicated that MET (hepatocyte growth factor receptor), whose high level positively correlates with the more aggressive melanoma phenotype, promotes the activation of signaling pathways leading to the mobilization of neutrophils in response to cancer immunotherapies. The gene discussed is MET; the disease is melanoma.